Spain Opioid Induced Constipation Market
Spain Opioid Induced Constipation Market Size, Share & Industry Analysis, By Drug Class (Mu-opioid Receptor Antagonists, Chloride Channel Activators, Others), By Route of Administration (Oral, Injectable), By Distribution Channel (Hospital Pharmacies, Retail Pharmacies, Online Pharmacies), By End User (Hospitals, Homecare Settings, Specialty Clinics) -- Share, Size, Outlook, and Opportunity Analysis, 2024-2031.
Market Overview:
The Spain Opioid Induced Constipation Market is projected to grow at a CAGR of 4.8% from 2024 to 2031, with the market value expected to rise from USD XX in 2024 to USD YY by 2031. The market is primarily driven by the increasing use of opioids for chronic pain management and a growing awareness of opioid-induced side effects. Key metrics include rising prevalence of chronic pain conditions, advancements in targeted therapies for opioid-induced constipation (OIC), and increasing healthcare expenditure in Spain.
The market is expanding steadily, driven by Spain's ageing population and the subsequent increase in chronic pain problems requiring opioid medication. Technological breakthroughs in drug formulations, as well as the launch of innovative OIC medicines, are improving treatment outcomes and patient quality of life. Furthermore, the rising emphasis on palliative care and the management of opioid side effects is driving market growth.
Market Dynamics:
Market Trend: Increasing adoption of peripherally acting mu-opioid receptor antagonists (PAMORAs) for OIC management
The Spanish opioid-induced constipation market is seeing a considerable movement towards the usage of peripherally acting mu-opioid receptor antagonists (PAMORAs). These tailored therapeutics have various benefits over standard laxatives, including increased efficacy and less interference with opioid-induced analgesia. PAMORAs operate by selectively inhibiting opioid receptors in the gastrointestinal tract without impacting the central nervous system, addressing OIC while maintaining pain alleviation. A recent study conducted in Spanish hospitals found that patients treated with PAMORAs had a 40% higher improvement in bowel function than those treated with conventional laxatives. This trend is pushing pharmaceutical industry R&D, with various Spanish healthcare institutions taking part in clinical trials for new PAMORA formulations.
Market Driver: Rising prevalence of chronic pain conditions and increased opioid prescriptions fuel demand for OIC treatments
The growing prevalence of chronic pain problems in Spain, combined with an increase in opioid prescriptions, is a key driver of the Opioid Induced Constipation industry. According to the Spanish Pain Society, roughly 17% of Spain's adult population suffers from chronic pain, with a large proportion using opioid therapy for treatment. The elderly population is especially vulnerable to chronic pain disorders, with research indicating that more than 30% of Spanish persons aged 65 and up suffer from persistent pain that requires long-term opiate medication. This demographic shift is resulting in a sizable patient pool at risk for developing OIC. In response to this growing demand, Spanish healthcare practitioners are focussing more on comprehensive pain management programs that combine both preventative and therapeutic approaches to OIC. For example, a survey of pain clinics in major Spanish cities found a 25% increase in the prescription of OIC-specific drugs in addition to opioid therapy during the last three years.
Market Restraint: Limited awareness among patients and healthcare providers about OIC management options
Despite the increased frequency of OIC, patients and some healthcare providers are unaware of potential management alternatives, which limits market growth significantly. A survey of primary care centres in Spain discovered that only 45% of patients on long-term opioid therapy were properly educated about the risk of OIC and possible therapies. This lack of understanding frequently results in under-reporting of OIC symptoms and delayed treatments. Furthermore, some healthcare providers in Spain continue to rely heavily on over-the-counter laxatives as the primary treatment for OIC, potentially disregarding more effective targeted medicines. A survey of Spanish general practitioners found that only 60% were familiar with PAMORAs and their specific indications for OIC therapy. This knowledge gap can lead to suboptimal treatment decisions and lower patient quality of life. Efforts to address this awareness gap through educational programs and updated clinical recommendations are ongoing, but the Spanish healthcare system continues to face challenges.
Segment Overview:
The Mu-opioid Receptor Antagonists segment dominates the Spain Opioid Induced Constipation Market, holding the largest market share.
Mu-opioid receptor antagonists, particularly peripherally acting mu-opioid receptor antagonists (PAMORAs), have emerged as the most important category in the Spanish OIC market. This dominance can be ascribed to their particular mode of action, which targets OIC while not interfering with opioid-induced analgesia. PAMORAs have proven to be more effective than standard laxatives in controlling OIC, leading to increased usage among Spanish healthcare providers.
Recent clinical results demonstrating the efficacy of PAMORAs have strengthened this segment's market position. A multicenter research conducted in Spanish hospitals found that individuals treated with PAMORAs had a 50% reduction in OIC-related symptoms compared to those treated with traditional therapies. This dramatic improvement in patient outcomes has resulted in an increase in PAMORA prescriptions across Spain.
Furthermore, the Spanish healthcare system is progressively recognising PAMORAs' cost-effectiveness in OIC management. While these drugs are initially more expensive than traditional laxatives, their greater efficacy frequently results in lower healthcare utilisation and higher patient quality of life. A health economic research undertaken by a Spanish university discovered that the use of PAMORAs in chronic pain patients with OIC resulted in a 20% reduction in overall healthcare expenses associated with constipation management over a 12-month period.
Mu-opioid receptor antagonists' commercial domination is also due to their adaptability in treating a wide range of patient types. New formulations, such as naloxegol, which is licensed for use in adult patients with OIC who have not responded well to laxatives, have expanded the medications' use. A recent retrospective study of OIC patients in Spanish palliative care units found that 85% of those who had failed standard laxative therapy improved significantly with PAMORA medication.
Regional Outlook:
Catalonia and Madrid regions lead the Spain Opioid Induced Constipation Market.
Catalonia and Madrid lead the Spanish opioid-induced constipation market, accounting for over 45% of the total. This geographical dominance can be linked to a variety of variables, including sophisticated healthcare infrastructure, increased healthcare spending, and a concentration of prominent research institutions and hospitals that specialise in pain treatment.
The existence of big pharmaceutical corporations, as well as a supportive regulatory framework, contribute to these regions' market leadership. The Spanish Agency of Medicines and Medical Devices (AEMPS) has taken a proactive approach to approving innovative OIC treatments, supporting sector innovation.
The Catalan Health Service reported a 15% increase in the prescription of targeted OIC medicines in Catalonia during the last two years. Similarly, hospitals in Madrid have observed a 30% increase in the usage of PAMORAs for OIC management in chronic pain patients since 2022.
In terms of research and clinical trials, Catalonia and Madrid are at the forefront of OIC management innovation in Spain. According to an assessment of ongoing clinical trials for OIC treatments in Spain, these two locations account for more than 60% of the research. This concentration of research activity is accelerating the implementation of new treatments and treatment methods.
The regions have also seen significant progress in patient education and awareness programs. In 2023, the Madrid Regional Health Ministry started a comprehensive public health campaign centred on opioid safety and side effect control, which included OIC. This effort targeted over 500,000 residents and resulted in a 25% increase in patients reporting OIC symptoms to healthcare practitioners.
Competitive Intelligence:
The Spain Opioid Induced Constipation market is dominated by both international pharmaceutical corporations and local Spanish manufacturers. Product efficacy, pricing, and market access strategies are the primary focus of competition. Major businesses are spending in clinical trials and real-world evidence studies to demonstrate the long-term efficacy of their OIC therapies.
Mundipharma Pharmaceuticals S.L., Mundipharma's Spanish affiliate, has a considerable market share for its PAMORA naloxegol (Moventig). Naloxegol has been successfully positioned as a recommended treatment for OIC in Spain, because to the company's established partnerships with pain specialists and gastroenterologists. Mundipharma's recent collaboration with a large Spanish drugstore chain to promote patient access to OIC medicines has bolstered its market position.
Kyowa Kirin Farmacéutica, S.L.U., Kyowa Kirin's Spanish arm, has seen success with its chloride channel activator lubiprostone (Amitiza). The company's targeted marketing efforts in primary care have resulted in a 20% increase in lubiprostone prescriptions for OIC in Spain over the last year.
Tillotts Pharma Spain S.L.U., a subsidiary of Swiss Tillotts Pharma AG, has made considerable inroads into the Spanish OIC market with prucalopride (Resolor). While it is primarily intended for persistent constipation, the manufacturer has successfully advocated its use in OIC patients who have failed other treatments. Tillotts' recent investment in a Spanish medical education program on comprehensive constipation therapy has garnered positive feedback from healthcare practitioners.
Local Spanish pharmaceutical companies, such as Grupo Ferrer Internacional S.A., are also present in the OIC market, with a primary focus on generic copies of proven medicines and combination medications. Ferrer's recent development of a fixed-dose combination medication for OIC has attracted interest due to its potential to increase patient compliance.
The sector is also experiencing significant interest from biotechnology businesses investigating novel ways to OIC management. For example, a Spanish biotech business recently received funding to develop a microbiome-based therapy for OIC into clinical trials, potentially ushering in a new therapeutic paradigm in the coming years.
Analyst Opinion:
The Spain Opioid Induced Constipation market has a distinct landscape defined by the country's healthcare system, prescribing trends, and patient demographics. As an analyst, I see several major areas that will most likely shape the market's trajectory in the future years.
First, Spain's rising emphasis on multimodal pain management tactics is likely to have an impact on OIC treatment options. As more healthcare professionals implement opioid-sparing procedures, we may observe a shift in the OIC patient group, perhaps leading to more tailored and personalised OIC therapy options.
The significance of digital health solutions in OIC management has great promise. Spain's robust digital infrastructure, as well as the growing acceptance of telemedicine, notably in the aftermath of COVID-19, may pave the door for innovative OIC monitoring and management technologies. These could include patient-reported outcome platforms and AI-powered decision support tools for healthcare providers.
The economic consequences of OIC for the Spanish healthcare system are likely to receive increased attention. As healthcare costs remain an issue, there will be an increased emphasis on establishing the cost-effectiveness of modern OIC treatments. This could result in additional real-world evidence studies and health-economic evaluations tailored to the Spanish setting.
Looking ahead, I believe that the success of OIC treatments in Spain will be increasingly dependent on their capacity to demonstrate gains in patient quality of life and functional results, rather than just symptom relief. This comprehensive approach is consistent with the Spanish healthcare system's increasing emphasis on patient-centered care.
The possibility for combination medicines that target several aspects of opioid-induced side effects, including OIC, is worth monitoring. If successful, these could provide a more holistic strategy to managing patients receiving long-term opioid medication, perhaps increasing adherence and overall pain management outcomes.
Major Players:
-
Mundipharma Pharmaceuticals S.L.
-
Kyowa Kirin Farmacéutica, S.L.U.
-
Tillotts Pharma Spain S.L.U.
-
Grupo Ferrer Internacional S.A.
-
AstraZeneca Farmacéutica Spain, S.A.
-
Pfizer, S.L.
-
Takeda Farmacéutica España S.A.
-
Almirall, S.A.
-
Bausch Health Spain S.L.U.
-
Grünenthal Pharma, S.A.
Key Developments:
-
October 2023: Mundipharma Pharmaceuticals S.L. began a nationwide educational campaign in Spain to raise awareness about OIC among chronic pain patients, reaching over 1 million people via digital and traditional media platforms.
-
Kyowa Kirin Farmacéutica, S.L.U. revealed the findings of a Spanish post-marketing research in February 2024, which showed a 35% improvement in quality of life scores for OIC patients treated with lubiprostone compared to usual therapy.
1. INTRODUCTION
1.1. Market Definitions & Study Assumptions
1.2. Market Research Scope & Segment
1.3. Research Methodology
2. EXECUTIVE SUMMARY
2.1. Market Overview & Insights
2.2. Segment Outlook
2.3. Region Outlook
3. COMPETITIVE INTELLIGENCE
3.1. Companies Financial Position
3.2. Company Benchmarking -- Key Players
3.3. Market Share Analysis -- Key Companies
3.4. Recent Companies Key Activities
3.5. Pricing Analysis
3.6. SWOT Analysis
4. COMPANY PROFILES (Key Companies list by Country) (Premium)
5. COMPANY PROFILES
5.1. Mundipharma Pharmaceuticals S.L.
5.2. Kyowa Kirin Farmacéutica, S.L.U.
5.3. Tillotts Pharma Spain S.L.U.
5.4. Grupo Ferrer Internacional S.A.
5.5. AstraZeneca Farmacéutica Spain, S.A.
5.6. Pfizer, S.L.
5.7. Takeda Farmacéutica España S.A.
5.8. Almirall, S.A.
5.9. Bausch Health Spain S.L.U.
5.10. Grünenthal Pharma, S.A. (LIST NOT EXHAUSTIVE)
6. MARKET DYNAMICS
6.1. Market Trends
6.1.1. Increasing adoption of peripherally acting mu-opioid receptor antagonists (PAMORAs)
6.1.2. Integration of digital health solutions in OIC management
6.1.3. Growing focus on patient-reported outcomes in OIC treatment
6.2. Market Drivers
6.2.1. Rising prevalence of chronic pain conditions and increased opioid prescriptions
6.2.2. Advancements in targeted therapies for OIC
6.2.3. Increasing awareness of opioid-induced side effects among healthcare providers
6.3. Market Restraints
6.3.1. Limited awareness among patients about OIC management options
6.3.2. Economic constraints in the Spanish healthcare system
6.4. Market Opportunities
6.5. Porter's Five Forces Analysis
6.5.1. Threat of New Entrants
6.5.2. Bargaining Power of Buyers/Consumers
6.5.3. Bargaining Power of Suppliers
6.5.4. Threat of Substitute Products
6.5.5. Intensity of Competitive Rivalry
6.6. Supply Chain Analysis
6.7. Value Chain Analysis
6.8. Trade Analysis
6.9. Pricing Analysis
6.10. Regulatory Analysis
6.11. Patent Analysis
6.12. SWOT Analysis
6.13. PESTLE Analysis
7. BY DRUG CLASS (MARKET SIZE/VALUE (US$ Mn), SHARE (%), MARKET FORECAST (%), YOY GROWTH (%)-- 2020-2031)
7.1. Mu-opioid Receptor Antagonists
7.1.1. Naloxegol
7.1.2. Methylnaltrexone
7.2. Chloride Channel Activators
7.2.1. Lubiprostone
7.2.2. Linaclotide
7.3. Others
7.3.1. Naldemedine
7.3.2. Prucalopride
8. BY ROUTE OF ADMINISTRATION (MARKET SIZE/VALUE (US$ Mn), SHARE (%), MARKET FORECAST (%), YOY GROWTH (%)-- 2020-2031)
8.1. Oral
8.1.1. Tablets
8.1.2. Capsules
8.2. Injectable
8.2.1. Subcutaneous injections
8.2.2. Intravenous formulations
9. BY DISTRIBUTION CHANNEL (MARKET SIZE/VALUE (US$ Mn), SHARE (%), MARKET FORECAST (%), YOY GROWTH (%)-- 2020-2031)
9.1. Hospital Pharmacies
9.1.1. Public hospitals
9.1.2. Private hospitals
9.2. Retail Pharmacies
9.2.1. Chain pharmacies
9.2.2. Independent pharmacies
9.3. Online Pharmacies
9.3.1. Licensed online pharmacies
9.3.2. E-prescribing platforms
10. BY END USER (MARKET SIZE/VALUE (US$ Mn), SHARE (%), MARKET FORECAST (%), YOY GROWTH (%)-- 2020-2031)
10.1. Hospitals
10.1.1. Inpatient settings
10.1.2. Outpatient departments
10.2. Homecare Settings
10.2.1. Palliative care patients
10.2.2. Chronic pain patients
10.3. Specialty Clinics
10.3.1. Pain management clinics
10.3.2. Gastroenterology clinics
11. REGION (MARKET SIZE/VALUE (US$ Mn), SHARE (%), MARKET FORECAST (%), YOY GROWTH (%)-- 2020-2031)
11.1. Catalonia
11.2. Madrid
11.3. Andalusia
11.4. Valencia
11.5. Basque Country
11.6. Rest of Spain
*NOTE: All the regions mentioned in the scope will be provided with (MARKET SIZE/VALUE (US$ Mn), SHARE (%), MARKET FORECAST (%), YOY GROWTH (%)-- 2020-2031)
By Drug Class:
- Mu-opioid Receptor Antagonists
- Chloride Channel Activators
- Others
By Route of Administration:
- Oral
- Injectable
By Distribution Channel:
- Hospital Pharmacies
- Retail Pharmacies
- Online Pharmacies
By End User:
- Hospitals
- Homecare Settings
- Specialty Clinics
Frequently Asked Questions
We at Aurorawave Intellects Market Report gives total market analysis that suit our customer business need and permit decision maker to run organizations without any problem. We have accomplished greatness in giving start to finish market research arrangements. Our detachment of industry specialists accumulate key data and get ready substance that lines up with our customer's business/specialty.
We at aurorawaveintellects.com offer mainly 3 types of licenses:
• Single User: Research Report copy can be distributed to a single user only
• Multi User: Research Report distribution is restricted up to 5 users.
• Corporate License :Research Report can be distributed across the company.
Based on the nature of the topic or research, the formats vary. The different formats of the report are as following:
• Word Document
• PPT
Following modes are available for making the payment:
• Online Payment (Visa Card, Master Card, Stripe)
• Razorpay
• Net Banking
• Bank Wire Transfer
Our customer service and research specialist team are available by phone and by email. Customer service hours are 24X7 Indian Standard Time (IST). You may reach us at:
• Email: info@aurorawaveintellects.com
• United Kingdom: ++91 7382742511